{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:14:03Z","timestamp":1787015643870,"version":"build-2736575974"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The second-generation antipsychotic quetiapine has been demonstrated to undergo gestation-related changes in pharmacokinetics. This study applied pharmacokinetic modelling principles to investigate the mechanism of these changes and to propose new dosing strategies to counteract these changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A pharmacokinetic modelling approach was implemented using virtual population groups. Changes in quetiapine trough plasma concentration during gestation were quantified across all trimesters, and dose adjustment strategies were applied to counteract these changes by targeting a therapeutic range of 50\u2013500 ng\/ml throughout gestation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>The application of the model during gestation predicted a decrease in trough concentration. A maximum decrease of 58% was predicted during trimester 2, and being associated with a statistically significant decrease in oral clearance at gestation week 25, 204 l\/h \u00b1 100.8 l\/h compared with non-pregnant subjects, 121.9 l\/h \u00b1 51.8 l\/h. A dosing optimisation strategy identified that dose increases to 500\u2013700 mg twice daily would result in 32\u201355% of subjects possessing trough concentration in excess of 50 ng\/ml.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Quetiapine doses in pregnancy should be increased to 500\u2013700 mg twice daily to counteract a concomitant increase in metabolic clearance, increase in volume of distribution and decrease in plasma protein binding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jphp.13236","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T15:42:43Z","timestamp":1580744563000},"page":"670-681","source":"Crossref","is-referenced-by-count":12,"title":["Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study"],"prefix":"10.1093","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-9324","authenticated-orcid":false,"given":"Raj K S","family":"Badhan","sequence":"first","affiliation":[{"name":"Medicines Optimisation Research Group, Aston Pharmacy School, Aston University , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Macfarlane","sequence":"additional","affiliation":[{"name":"Medicines Optimisation Research Group, Aston Pharmacy School, Aston University , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"2024103012343563700_jphp13236-cit-0001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1997.tb10162.x","article-title":"A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"96","author":"Peuskens","year":"1997","journal-title":"Acta Psychiatr Scand"},{"key":"2024103012343563700_jphp13236-cit-0002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0003","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2393-14-242","article-title":"Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance","volume":"14","author":"Hanley","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"key":"2024103012343563700_jphp13236-cit-0004","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/ajo.12129","article-title":"Review of calls to an Australian teratogen information service regarding psychotropic medications over a 12-year period","volume":"53","author":"Kennedy","year":"2013","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2024103012343563700_jphp13236-cit-0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcpt.12372","article-title":"Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review","volume":"116","author":"Ennis","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2024103012343563700_jphp13236-cit-0006","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group","volume":"54","author":"Small","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0007","doi-asserted-by":"crossref","first-page":"h5918","DOI":"10.1136\/bmj.h5918","article-title":"Management of psychotropic drugs during pregnancy","volume":"532","author":"Chisolm","year":"2016","journal-title":"BMJ"},{"key":"2024103012343563700_jphp13236-cit-0008","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1067\/mob.2003.336","article-title":"Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study","volume":"189","author":"Andersson","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"2024103012343563700_jphp13236-cit-0009","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/154099903765448880","article-title":"Depressive symptoms among pregnant women screened in obstetrics settings","volume":"12","author":"Marcus","year":"2003","journal-title":"J Womens Health (Larchmt)"},{"key":"2024103012343563700_jphp13236-cit-0010","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1176\/appi.ajp.2007.06101639","article-title":"Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation","volume":"164","author":"Viguera","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpsyc.1995.03950150005001","article-title":"Neuroleptic withdrawal in schizophrenic patients. A review of the literature","volume":"52","author":"Gilbert","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0012","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archpsyc.1995.03950150021002","article-title":"Neuroleptic withdrawal in schizophrenic patients","volume":"52","author":"Baldessarini","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0013","volume-title":"Antenatal and postnatal mental health: clinical management and service guidance (Clinical guideline [CG192])","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"2024103012343563700_jphp13236-cit-0014","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0269881117699361","article-title":"British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017","volume":"31","author":"McAllister-Williams","year":"2017","journal-title":"J Psychopharmacol"},{"key":"2024103012343563700_jphp13236-cit-0015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/eb-2016-102373","article-title":"Perinatal suicide associated with depression diagnosis and absence of active treatment in 15-year UK national inquiry","volume":"19","author":"Kim","year":"2016","journal-title":"Evid Based Ment Health"},{"key":"2024103012343563700_jphp13236-cit-0016","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","article-title":"Antipsychotic use in pregnancy and the risk for congenital malformations","volume":"73","author":"Huybrechts","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1176\/appi.ajp.2015.15040506","article-title":"Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for atypical antipsychotics","volume":"173","author":"Cohen","year":"2016","journal-title":"Am J Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0018","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0920-9964(97)82567-4","article-title":"In vitro prediction of potential metabolic drug interactions for Seroquel","volume":"24","author":"Grimm","year":"1997","journal-title":"Schizophr Res"},{"key":"2024103012343563700_jphp13236-cit-0019","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.2008.1","article-title":"Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study","volume":"84","author":"Hebert","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"2024103012343563700_jphp13236-cit-0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/17425255.3.4.557","article-title":"Alterations in drug disposition during pregnancy: implications for drug therapy","volume":"3","author":"Hodge","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2024103012343563700_jphp13236-cit-0021","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1128\/AAC.01596-05","article-title":"Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women","volume":"50","author":"Hirt","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012343563700_jphp13236-cit-0022","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":"Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy","volume":"192","author":"Tracy","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"2024103012343563700_jphp13236-cit-0023","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.crd.0000102420.62200.e1","article-title":"Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation","volume":"12","author":"Qasqas","year":"2004","journal-title":"Cardiol Rev"},{"key":"2024103012343563700_jphp13236-cit-0024","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1471-0528.1973.tb02146.x","article-title":"Plasma volume in normal first pregnancy","volume":"80","author":"Pirani","year":"1973","journal-title":"J Obstet Gynaecol Br Commonw"},{"key":"2024103012343563700_jphp13236-cit-0025","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ajcn\/76.3.614","article-title":"The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution, or a decrease in albumin in a longitudinal study","volume":"76","author":"Murphy","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"2024103012343563700_jphp13236-cit-0026","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/ajkd.2002.30561","article-title":"Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia","volume":"39","author":"Hayashi","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2024103012343563700_jphp13236-cit-0027","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/clinchem\/35.9.1978","article-title":"Urinary excretion of some proteins and enzymes during normal pregnancy","volume":"35","author":"Cheung","year":"1989","journal-title":"Clin Chem"},{"key":"2024103012343563700_jphp13236-cit-0028","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cpt.770","article-title":"Treatment with antipsychotics in pregnancy: changes in drug disposition","volume":"103","author":"Westin","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2024103012343563700_jphp13236-cit-0029","volume-title":"Addendum to OSE Safety Review of Seroquel\u00ae (Quetiapine Fumarate) and Seroquel \u00ae XR (Quetiapine Fumarate Extended-Release)","author":"Baer","year":"2016"},{"key":"2024103012343563700_jphp13236-cit-0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/emj.19.1.31","article-title":"TOXBASE: poisons information on the internet","volume":"19","author":"Bateman","year":"2002","journal-title":"Emerg Med J"},{"key":"2024103012343563700_jphp13236-cit-0031","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","article-title":"Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling","volume":"51","author":"Abduljalil","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"2024103012343563700_jphp13236-cit-0032","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1365-2125.2012.04363.x","article-title":"A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4","volume":"74","author":"Gaohua","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012343563700_jphp13236-cit-0033","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/bdd.2081","article-title":"Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations","volume":"38","author":"Jogiraju","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"2024103012343563700_jphp13236-cit-0034","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2174\/138920012800840374","article-title":"Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings","volume":"13","author":"Lu","year":"2012","journal-title":"Curr Drug Metab"},{"key":"2024103012343563700_jphp13236-cit-0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bdd.1899","article-title":"Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents","volume":"35","author":"Johnson","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"2024103012343563700_jphp13236-cit-0036","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/dmd.108.023291","article-title":"Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5","volume":"37","author":"Bakken","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"2024103012343563700_jphp13236-cit-0037","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40262-016-0367-6","article-title":"Development of a physiologically based pharmacokinetic\/pharmacodynamic model to predict the impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics represented by receptor\/transporter occupancy of central nervous system drugs","volume":"55","author":"Alqahtani","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2024103012343563700_jphp13236-cit-0038","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"J Pharm Sci"},{"key":"2024103012343563700_jphp13236-cit-0039","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"2024103012343563700_jphp13236-cit-0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012343563700_jphp13236-cit-0041","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004714-200102000-00016","article-title":"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine","volume":"21","author":"Wong","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"2024103012343563700_jphp13236-cit-0042","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00004714-200204000-00011","article-title":"Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine","volume":"22","author":"Potkin","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"2024103012343563700_jphp13236-cit-0043","volume-title":"ATC\/DDD Index 2016","author":"WHO Collaborative Centre for Drug Statistics Methodology","year":"2016"},{"key":"2024103012343563700_jphp13236-cit-0044","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical pharmacokinetics of atypical antipsychotics: an update","volume":"57","author":"Mauri","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2024103012343563700_jphp13236-cit-0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"2024103012343563700_jphp13236-cit-0046","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service","volume":"68","author":"Castberg","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0047","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4088\/JCP.v61n0403","article-title":"Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders","volume":"61","author":"McConville","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0048","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cap.2007.0084","article-title":"Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders","volume":"18","author":"Winter","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2024103012343563700_jphp13236-cit-0049","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00007691-200410000-00005","article-title":"Quetiapine serum concentrations in psychiatric patients: the influence of comedication","volume":"26","author":"Hasselstrom","year":"2004","journal-title":"Ther Drug Monit"},{"key":"2024103012343563700_jphp13236-cit-0050","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.09r05739yel","article-title":"Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review","volume":"72","author":"Sparshatt","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 12","key":"2024103012343563700_jphp13236-cit-0051","first-page":"5","article-title":"The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary","volume":"64","author":"Kane","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0052","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.schres.2008.01.013","article-title":"Quetiapine at high doses for the treatment of refractory schizophrenia","volume":"101","author":"Boggs","year":"2008","journal-title":"Schizophr Res"},{"key":"2024103012343563700_jphp13236-cit-0053","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/JCP.0b013e31820f4fe0","article-title":"A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg\/d for patients with treatment-resistant schizophrenia or schizoaffective disorder","volume":"31","author":"Lindenmayer","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"2024103012343563700_jphp13236-cit-0054","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4088\/JCP.10m06194","article-title":"A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder","volume":"73","author":"Honer","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JCP.0000000000000820","article-title":"Quetiapine dose adjustments in pregnant and postpartum women with bipolar disorder","volume":"38","author":"Pinheiro","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"2024103012343563700_jphp13236-cit-0056","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00737-006-0126-z","article-title":"Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding","volume":"9","author":"Gentile","year":"2006","journal-title":"Arch Womens Ment Health"},{"key":"2024103012343563700_jphp13236-cit-0057","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.pnpbp.2004.01.010","article-title":"Use of polypharmacotherapy in pregnancy: a prospective outcome in a case","volume":"28","author":"Yaris","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0058","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1176\/appi.ajp.160.3.588-a","article-title":"Safety of quetiapine during pregnancy","volume":"160","author":"Taylor","year":"2003","journal-title":"Am J Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0059","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1176\/appi.ajp.159.4.674","article-title":"Quetiapine and pregnancy","volume":"159","author":"Tenyi","year":"2002","journal-title":"Am J Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00737-007-0196-6","article-title":"Quetiapine use for the treatment of manic episode during pregnancy","volume":"10","author":"Cabuk","year":"2007","journal-title":"Arch Womens Ment Health"},{"key":"2024103012343563700_jphp13236-cit-0061","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","article-title":"Development and evaluation of a generic physiologically based pharmacokinetic model for children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"2024103012343563700_jphp13236-cit-0062","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/15287390490273550","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents","volume":"67","author":"Ginsberg","year":"2004","journal-title":"J Toxicol Environ Health A"},{"key":"2024103012343563700_jphp13236-cit-0063","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11592640-000000000-00000","article-title":"Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants","volume":"50","author":"Parrott","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2024103012343563700_jphp13236-cit-0064","volume-title":"Summary minutes of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology","author":"U.S. Food and Drug Administration","year":"2012"},{"key":"2024103012343563700_jphp13236-cit-0065","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.xphs.2018.10.056","article-title":"Dose optimization of chloroquine by pharmacokinetic modeling during pregnancy for the treatment of zika virus infection","volume":"108","author":"Olafuyi","year":"2019","journal-title":"J Pharm Sci"},{"key":"2024103012343563700_jphp13236-cit-0066","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2125.2006.02669.x","article-title":"Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women","volume":"62","author":"Villani","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012343563700_jphp13236-cit-0067","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0278-5846(00)00090-7","article-title":"Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment","volume":"24","author":"Thyrum","year":"2000","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0068","article-title":"Drugs as substances of metabolic enzymes: antipsychotics","volume-title":"Metabolic Drug Interactions","author":"DeVane","year":"2000"},{"key":"2024103012343563700_jphp13236-cit-0069","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002130050492","article-title":"Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia","volume":"135","author":"Gefvert","year":"1998","journal-title":"Psychopharmacology"},{"key":"2024103012343563700_jphp13236-cit-0070","first-page":"137","article-title":"Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol","volume":"26","author":"Purdon","year":"2001","journal-title":"J Psychiatry Neurosci"},{"key":"2024103012343563700_jphp13236-cit-0071","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S0033291799001476","article-title":"A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, \u2018Seroquel\u2019) and haloperidol in schizophrenia","volume":"30","author":"Copolov","year":"2000","journal-title":"Psychol Med"},{"key":"2024103012343563700_jphp13236-cit-0072","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/13651500510014765","article-title":"Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up","volume":"9","author":"Nagy","year":"2005","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2024103012343563700_jphp13236-cit-0073","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.schres.2004.07.014","article-title":"High-dose quetiapine in treatment refractory schizophrenia","volume":"73","author":"Pierre","year":"2005","journal-title":"Schizophr Res"},{"key":"2024103012343563700_jphp13236-cit-0074","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/17843286.2016.1252546","article-title":"A case of dose escalation of quetiapine in persistent insomnia disorder","volume":"72","author":"Cornelis","year":"2017","journal-title":"Acta Clin Belg"},{"key":"2024103012343563700_jphp13236-cit-0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11126-012-9248-9","article-title":"Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and\/or cytochrome P4502D6","volume":"84","author":"Khazaal","year":"2013","journal-title":"Psychiatr Q"},{"key":"2024103012343563700_jphp13236-cit-0076","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.pnpbp.2007.01.006","article-title":"Quetiapine dosage in bipolar disorder episodes and mixed states","volume":"31","author":"Khazaal","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0077","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0196-0644(03)00600-0","article-title":"Quetiapine poisoning: a case series","volume":"42","author":"Balit","year":"2003","journal-title":"Ann Emerg Med"},{"key":"2024103012343563700_jphp13236-cit-0078","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3109\/15563659809028056","article-title":"Loss of consciousness from acute quetiapine overdosage","volume":"36","author":"Harmon","year":"1998","journal-title":"J Toxicol Clin Toxicol"},{"key":"2024103012343563700_jphp13236-cit-0079","volume-title":"Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS)","author":"Williams","year":"2003"},{"key":"2024103012343563700_jphp13236-cit-0080","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archpsyc.1978.01770310043002","article-title":"A diagnostic interview: the schedule for affective disorders and schizophrenia","volume":"35","author":"Endicott","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0081","volume-title":"Consensus Statement on High-Dose Antipsychotic Medication","author":"Royal College of Psychiatrists","year":"2014"},{"key":"2024103012343563700_jphp13236-cit-0082","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"2024103012343563700_jphp13236-cit-0083","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.172.1.11","article-title":"Health of the Nation Outcome Scales (HoNOS): research and development","volume":"172","author":"Wing","year":"1998","journal-title":"Br J Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0084","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1192\/bjp.166.5.650","article-title":"A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients","volume":"166","author":"Day","year":"1995","journal-title":"Br J Psychiatry"},{"key":"2024103012343563700_jphp13236-cit-0085","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1080\/14767058.2016.1256991","article-title":"Prophylactic use of olanzapine and quetiapine from pregnancy to the postpartum period in women with bipolar disorder: a case series","volume":"30","author":"Uguz","year":"2017","journal-title":"J Matern Fetal Neonatal Med"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.13236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jphp.13236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jphp.13236","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/5\/670\/60225698\/jphp13236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/5\/670\/60225698\/jphp13236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:54:07Z","timestamp":1730296447000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/72\/5\/670\/6122052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":85,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.13236","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5,1]]}}}